INDICATED FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
ADMINISTERED INTRAVENOUSLY OVER 2 TO 10 MINUTES, ON TWO CONSECUTIVE DAYS, EACH WEEK FOR THREE WEEKS (DAYS 1, 2, 8, 9, 15, AND 16), FOLLOWED BY A 12-DAY REST PERIOD (DAYS 17 TO 28). EACH 28-DAY PERIOD IS CONSIDERED ONE TREATMENT CYCLE.
IN CYCLE 1, CARFILZOMIB IS ADMINISTERED AT A DOSE OF 20 MG/MΒ². IF TOLERATED IN CYCLE 1, THE DOSE SHOULD BE ESCALATED TO 27 MG/MΒ² BEGINNING IN CYCLE 2 AND CONTINUED AT 27 MG/MΒ² IN SUBSEQUENT CYCLES. TREATMENT MAY BE CONTINUED UNTIL DISEASE PROGRESSION OR UNTIL UNACCEPTABLE TOXICITY OCCURS. HYDRATE PATIENTS TO REDUCE THE RISK OF RENAL TOXICITY AND OF TUMOR LYSIS SYNDROME (TLS).
PRE-MEDICATE WITH DEXAMETHASONE 4 MG ORALLY OR INTRAVENOUSLY PRIOR TO ALL DOSES OF CARFILZOMIB DURING CYCLE 1 AND PRIOR TO ALL CARFILZOMIB DOSES DURING THE FIRST CYCLE OF DOSE ESCALATION TO 27 MG/MΒ² TO REDUCE THE INCIDENCE AND SEVERITY OF INFUSION REACTIONS